Visit Toujeo.com for more information.
For this edition of Sanofi Stories, we spoke with Heather Lee Whipple, Senior Director, US Market Access at Sanofi US about navigating dynamic change in healthcare. Check it out to learn more.
Sanofi US is voluntarily recalling all Auvi-Q® (epinephrine injection, USP). The recall involves all Auvi-Q® currently on the market and includes both the 0.15 mg and 0.3 mg strengths for hospitals, retailers and consumers.
Last update: April 15, 2016